NCT06008275 - Neratinib in Combination With Ruxolitinib in Patients With mTNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Triple-Negative Breast CarcinomaBreast Cancer

Interventions

DRUG

Neratinib Oral Tablet

240mg oral daily. Dosing will follow standard dose escalation procedures

DRUG

Ruxolitinib Oral Tablet

20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure

Trial Locations (1)

RECRUITING

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas